Self-developed AI algorithm & clinical AI screening assistant

2019-10-30

Biomdcare takes advantage of the high quality medical service and technology in Taiwan to integrate knowhows and experts from different domains to build our exceptional solutions, platforms and tools for our clients.

The company offers advanced and applicable solutions and tools to its clients to assist them to build their own futuristic autonomous clinics and conduct biological prospective research, AI pathological examination, evidence-based medicine, cohort study, and clinical trials.

  • Self-developed deep learning model computing technology, allowing low resource computing and multi GPU optimized algorithm.
  • Artificial intelligence big data evidence-based causal analysis algorithm and 6000+ Chinese disease and medical model.
  • 20+ AISaMD technology and products and AI related patents in China, USA, Japan, and Taiwan.
  • Developing AI Screening Assistant on Leukemia, Cervical Cancer, and Osteoporosis with Tai Cheng Cell Therapy Center, Cardinal Tien Hospital, and Taipei Municipal Wanfang Hospital respectively.

 

 

Welcome to R223 for the services and further collaborations with Biomdcare Corporation.

 

》Cooperation projects and needs:Looking for Collaboration on "Self-Developed AI Algorithm & Clinical AI Screening Assistant"